This study is a prospective randomized trial with 242 IUI cycles. Patients are randomized in two groups including 121 cycles in each group. A total of 255 cycles in 167 patients are finally recruited. In the first group, the patients will be treated with triptorelin (Gonapeptyl®) in their luteal phase. As for the other group, the patients will undergo the luteal phase without any supportive medication. This study is going to clarify the role of the gonadotropin agonist (triptorelin acetate, Gonapeptyl®) as a luteal phase supporter. The benefit of the treatment is measured by the numbers in the live birth and clinical pregnancy rates.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
167
Triptorelin 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
Tampere University Hospital
Tampere, Finland
Live birth rate
Time frame: At possible delivery (about 40 weeks)
Ongoing pregnancy rate
Time frame: After two weeks
Miscarriage rate
Time frame: During subsequent about 40 weeks of pregnancy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.